KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Prepaid Assets (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Prepaid Assets for 8 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 667.24% year-over-year to $4.5 million, compared with a TTM value of $4.5 million through Dec 2025, up 667.24%, and an annual FY2025 reading of $4.5 million, up 667.24% over the prior year.
  • Prepaid Assets was $4.5 million for Q4 2025 at Esperion Therapeutics, up from $2.8 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $14.4 million in Q3 2024 and bottomed at $193000.0 in Q4 2023.
  • Average Prepaid Assets over 5 years is $3.8 million, with a median of $2.8 million recorded in 2025.
  • The sharpest move saw Prepaid Assets plummeted 96.18% in 2022, then skyrocketed 1094.84% in 2025.
  • Year by year, Prepaid Assets stood at $11.2 million in 2021, then crashed by 90.82% to $1.0 million in 2022, then crashed by 81.19% to $193000.0 in 2023, then soared by 203.63% to $586000.0 in 2024, then surged by 667.24% to $4.5 million in 2025.
  • Business Quant data shows Prepaid Assets for ESPR at $4.5 million in Q4 2025, $2.8 million in Q3 2025, and $4.2 million in Q2 2025.